KOLs have traditionally exerted their influence through research and publication on drug safety and efficacy, but now share the stage with other important measures.
Paul Chew, MD
Advertisement
Articles by Paul Chew, MD
A discussion of the cost and time put into clinical trials.
Advertisement
Latest Updated Articles
Clinical Trials Don't Have to Cost Too Much or Take Too LongPublished: May 8th 2018 | Updated:
- KOLs: An Endangered Buzzword
Published: March 20th 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
3
FDA Approves Blenrep for Treatment of Replapsed/Refractory Multiple Myeloma
4
Could DTC Programs Help Simplify the Drug-Pricing System?
5
